Triptan therapy in migraine

New England Journal of Medicine

Volumn 363, Issue 1, 2010, Pages 63-70

  Loder, Elizabeth ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; AMARGE; ANALGESIC AGENT; BARBITURIC ACID DERIVATIVE; CAFFEINE; DOMPERIDONE; ELETRIPTAN; ERGOT DERIVATIVE; ERGOTAMINE; FROVATRIPTAN; METOCLOPRAMIDE; NARATRIPTAN; NORADRENALIN UPTAKE INHIBITOR; OPIATE DERIVATIVE; PLACEBO; RIZATRIPTAN; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ASTHENIA; BIRTH DEFECT; CARDIOVASCULAR DISEASE; CHEST TIGHTNESS; CLINICAL TRIAL; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; EMERGENCY WARD; FLUSHING; HEAD AND NECK DISEASE; HEADACHE; HEALTH CARE COST; HUMAN; MEDICAL SPECIALIST; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NAUSEA; NECK TIGHTNESS; PARESTHESIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; SOMNOLENCE; THERAPY EFFECT; THORAX PAIN;

EID: 77954210204     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMct0910887     Document Type: Review

References (50)

1. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24:Suppl 1:9-160.
2. The global burden of disease: 2004 update. Geneva: World Health Organization, 2008. (Accessed June 4, 2010, at http://www.who.int/healthinfo/ global-burden-disease/GBD-report-2004update-full.pdf.)
3. Linet MS, Stewart WF, Celentano DD, Ziegler D, Sprecher M. An epidemiologic study of headache among adolescents and young adults. JAMA 1989;261:2211-6. (Pubitemid 19101405)
4. Stewart WF, Wood C, Reed ML, Roy J, Lipton RB. Cumulative lifetime migraine incidence in women and men. Cephalalgia 2008;28:1170-8.
5. Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009;339:b3914.
6. Adeney KL, Williams MA. Migraine headaches and preeclampsia: an epidemiologic review. Headache 2006;46:794-803.
7. Linde M, Dahlöf C. Attitudes and burden of disease among self-considered migraineurs - a nation-wide populationbased survey in Sweden. Cephalalgia 2004;24:455-65.
8. Goldstein JN, Camargo CA Jr, Pelletier AJ, Edlow JA. Headache in United States emergency departments: demographics, work-up and frequency of pathological diagnoses. Cephalalgia 2006;26:684-90.
9. Pitts SR, Niska RW, Xu J, Burt CW. National Hospital Ambulatory Medical Care Survey: 2006 emergency department summary. Natl Health Stat Rep 2008;6:1-38.
10. Hing E, Cherry DK, Woodwell DA. National Ambulatory Medical Care Survey: 2004 summary. Advance data from vital and health statistics. No. 374. Hyattsville, MD: National Center for Health Statistics, 2006.
11. Hawkins K, Wang S, Rupnow M. Direct cost burden among insured US employees with migraine. Headache 2008;48:553-63.
12. Hawkins K, Wang S, Rupnow M. Idem. Indirect cost burden of migraine in the United States. J Occup Environ Med 2007;49:368-74.
13. Goadsby PJ. The vascular theory of migraine - a great story wrecked by the facts. Brain 2009;132:6-7.
14. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med 2002;346:257-70.
15. Sprenger T, Goadsby PJ. Migraine pathogenesis and state of pharmacological treatment options. BMC Med 2009;7:71.
16. Afridi SK, Matharu MS, Lee L, et al. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain 2005;128:932-9.
17. Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci U S A 2004;101:4274-9.
18. Shields KG, Goadsby PJ. Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a migraine target? Neurobiol Dis 2006;23:491-501.
19. Bartsch T, Knight YE, Goadsby PJ. Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol 2004;56:371-81. (Pubitemid 39166556)
20. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000;60:1259-87. (Pubitemid 32039386)
21. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-58.
22. Lipton RB, Bigal ME, Goadsby PJ. Double-blind clinical trials of oral triptans vs other classes of acute migraine medication - a review. Cephalalgia 2004;24:321-32.
23. Diener HC, Jansen JP, Reches A, et al. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, doubleblind, placebo-controlled comparison. Eur Neurol 2002;47:99-107.
24. Geraud G, Compagnon A, Rossi A. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. Eur Neurol 2002;47:88-98.
25. Tfelt-Hansen PC. Unpublished clinical trials with sumatriptan. Lancet 2009;374:1501-2.
26. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-62. [Erratum, Neurology 2000;56:142.]
27. Cady RK, Freitag FG, Mathew NT, et al. Allodynia-associated symptoms, pain intensity and time to treatment: predicting treatment response in acute migraine intervention. Headache 2009;49:350-63.
28. Brandes JL, Cady RK, Freitag FG, et al. Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use. Headache 2009;49:1435-44.
29. Dodick DW. Triptan nonresponder studies: implications for clinical practice. Headache 2005;45:156-62.
30. Peroutka SJ. Beyond monotherapy: rational polytherapy in migraine. Headache 1998;38:18-22. (Pubitemid 28125003)
31. Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 2004;44:414-25.
32. Cunnington M, Ephross S, Churchill P. The safety of sumatriptan and naratriptan in pregnancy: what have we learned? Headache 2009;49:1414-22.
33. Källén B, Lygner PE. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache 2001;41:351-6.
34. Olesen C, Steffensen FH, Sorensen HT, Nielsen GL, Olsen J. Pregnancy outcome following prescription for sumatriptan. Headache 2000;40:20-4.
35. Public health advisory - combined use of 5-hydroxytryptamine receptor agonists (triptans), selective serotonin reuptake inhibitors (SSRIs) or selective serotonin/norepinephrine reuptake inhibitors (SNRIs) may result in life-threatening serotonin syndrome. Silver Spring, MD: Food and Drug Administration, 2006.
36. McKenzie JA, Cutrer FM. How well do headache patients remember? A comparison of self-report measures of headache frequency and severity in patients with migraine. Headache 2009;49:669-72.
37. Information for Vermont prescribers of prescription drugs: Zomig (zolmitriptan) tablets; Zomig ZMT (zolmitriptan) rapid dissolve tablets. AstraZeneca, 2009. (Accessed June 4, 2010, at http://www.astrazeneca-us.com/- mshost795281/content/980214/1447588/2112235/ZOMIG-ZOMIGZMT.)
38. Nappi G, Sandrini G, Sances G. Tolerability of the triptans: clinical implications. Drug Saf 2003;26:93-107.
39. Goadsby PJ, Dodick DW, Almas M, et al. Treatment-emergent CNS symptoms following triptan therapy are part of the attack. Cephalalgia 2007;27:254-62.
40. Welch KM, Mathew NT, Stone P, Rosamond W, Saiers J, Gutterman D. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 2000;20:687-95. [Erratum, Cephalalgia 2001;21:164-5.]
41. Hall GC, Brown MM, Mo J, MacRae KD. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004;62:563-8. (Pubitemid 38252796)
42. Silberstein SD, Dodick D, Kesslick J. Removing barriers to appropriate migraine treatment: formulary limitations and triptan package size. Headache 2005;45:1250-4.
43. Wammes-van der Heijden EA, Rahimtoola H, Leufkens HG, Tijssen CC, Egberts AC. Risk of ischemic complications related to the intensity of triptan and ergotamine use. Neurology 2006;67:1128-34.
44. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008;48:1157-68.
45. Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Neurology 1994;44:1587-92.
46. Aurora SK, Barrodale PM, McDonald SA, Jakubowski M, Burstein R. Revisiting the efficacy of sumatriptan therapy during the aura phase of migraine. Headache 2009;49:1001-4.
47. Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 2004;63:261-9.
48. Adelman JU, Calhoun A. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 2005;64:931. (Pubitemid 40316351)
49. Snow V, Weiss K, Wall EM, Mottur-Pilson C. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med 2002;137:840-9.
50. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol 2009;16:968-81.